Weight Loss Medication Phentermine-Induced Hypomania in Bipolar Depression
Prim Care Companion CNS Disord. 2024 Feb 20;26(1):23cr03624. doi: 10.4088/PCC.23cr03624.NO ABSTRACTPMID:38395144 | DOI:10.4088/PCC.23cr03624 (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - February 23, 2024 Category: Primary Care Authors: Wisam Al Jumaili Nibras Al Gburi Shailesh Jain Source Type: research
Phentermine in the Modern Era of Obesity Pharmacotherapy: Does It Still Have a Role in Treatment?
AbstractPurpose of ReviewThis review provides an overview of the history, mechanism of action, and expected treatment effects of the anti-obesity medication (AOM), phentermine. It also includes a summary of recent research and practical guidance for prescribing clinicians.Recent FindingsRecent research on phentermine is sparse and consists primarily of observational studies with methodologic limitations. These studies suggest that phentermine use is associated with clinically significant weight loss in adults and that the medication is generally well tolerated. Large-scale observational studies evaluating phentermine ’s ...
Source: Current Obesity Reports - January 3, 2024 Category: Eating Disorders & Weight Management Source Type: research
Early- and later-stage persistence with antiobesity medications: A retrospective cohort study
CONCLUSIONS: Later-stage persistence with AOM varies considerably based on the drug and the weight loss at 6 months.PMID:38053443 | DOI:10.1002/oby.23952 (Source: Obesity)
Source: Obesity - December 6, 2023 Category: Eating Disorders & Weight Management Authors: Hamlet Gasoyan Elizabeth R Pfoh Rebecca Schulte Phuc Le Michael B Rothberg Source Type: research
Early- and later-stage persistence with antiobesity medications: A retrospective cohort study
CONCLUSIONS: Later-stage persistence with AOM varies considerably based on the drug and the weight loss at 6 months.PMID:38053443 | DOI:10.1002/oby.23952 (Source: Obesity)
Source: Obesity - December 6, 2023 Category: Eating Disorders & Weight Management Authors: Hamlet Gasoyan Elizabeth R Pfoh Rebecca Schulte Phuc Le Michael B Rothberg Source Type: research
Abused drug-induced intracranial self-stimulation is correlated with the alteration of dopamine transporter availability in the medial prefrontal cortex and nucleus accumbens of mice
Biomed Pharmacother. 2023 Nov 8;169:115860. doi: 10.1016/j.biopha.2023.115860. Online ahead of print.ABSTRACTIntracranial self-stimulation (ICSS) of the medial forebrain bundle in mice is an experimental model use to assess the relative potential of reward-seeking behaviors. Here, we used the ICSS model to evaluate the abuse potential of 18 abused drugs: 3-Fluoroethamphetamine (3-FEA); methylphenidate; cocaine; dextroamphetamine; alpha-Pyrrolidinobutyrophenone (α-PBT); 4'-Fluoro-4-methylaminorex (4-FPO); methamphetamine; larocaine; phentermine; paramethoxymethamphetamine (PMMA); phendimetrazine; N-(1-adamantyl)-1-pentyl-1...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - November 10, 2023 Category: Drugs & Pharmacology Authors: Yong-Qing Zhang Hyun Kyu Min Eunchong Hong Eunhye Yu Sun Mi Gu Seong Shoon Yoon Dohyun Lee Jaejun Lee Jin Tae Hong Jaesuk Yun Source Type: research
Abused drug-induced intracranial self-stimulation is correlated with the alteration of dopamine transporter availability in the medial prefrontal cortex and nucleus accumbens of mice
Biomed Pharmacother. 2023 Nov 8;169:115860. doi: 10.1016/j.biopha.2023.115860. Online ahead of print.ABSTRACTIntracranial self-stimulation (ICSS) of the medial forebrain bundle in mice is an experimental model use to assess the relative potential of reward-seeking behaviors. Here, we used the ICSS model to evaluate the abuse potential of 18 abused drugs: 3-Fluoroethamphetamine (3-FEA); methylphenidate; cocaine; dextroamphetamine; alpha-Pyrrolidinobutyrophenone (α-PBT); 4'-Fluoro-4-methylaminorex (4-FPO); methamphetamine; larocaine; phentermine; paramethoxymethamphetamine (PMMA); phendimetrazine; N-(1-adamantyl)-1-pentyl-1...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - November 10, 2023 Category: Drugs & Pharmacology Authors: Yong-Qing Zhang Hyun Kyu Min Eunchong Hong Eunhye Yu Sun Mi Gu Seong Shoon Yoon Dohyun Lee Jaejun Lee Jin Tae Hong Jaesuk Yun Source Type: research
Potential drug-drug interactions with phentermine among long-term phentermine consumers: A retrospective analysis
CONCLUSION: There are patients who receive LT phentermine therapy despite the potential severe consequences that may result. These patients may receive concomitant therapy with phentermine and other pharmaceutical constituents, which may potentially cause DDIs, more specifically, moderate and severe DDIs. As such, these patients are not only confronted with the consequences of DDIs but are also at risk to experience ADRs as the residual effect of PDDIs.PMID:37882119 | DOI:10.7196/SAMJ.2023.v113i8.428 (Source: South African Medical Journal)
Source: South African Medical Journal - October 26, 2023 Category: African Health Authors: A Fourie M Julyan L Mostert J M Du Plessis Source Type: research
